Table 2.
Predictors of biochemical recurrence-free survival in patients with Nadir PSA < 0.06 ng/mL
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (≤ 70 versus > 70 years) | 0.530 (0.145–1.937) | 0.337 | – | – |
| T stage (T1-2 versus T3-4) | 3.074 (0.972–9.719) | 0.056 | 2.431 (0.712–8.297) | 0.156 |
| Gleason Score (≤ 7 versus 8–10) | 1.045 (0.340–3.211) | 0.939 | – | – |
| PSA at presentation (≤ 20 ng/mL versus > 20 ng/mL) | 1.088 (0.364–3.255) | 0.880 | – | – |
| Total ADT duration * | 0.327 (0.109–0.978) | 0.046 | 0.224 (0.070–0.720) | 0.012 |
| Time to nadir PSA (cut-off 6 months**) | 3.387 (1.041–11.023) | 0.043 | 4.369 (1.096–17.421) | 0.037 |
*Comparing the use of ADT for at least 12 months versus 9 months or less
**Median time to nadir PSA